Targeting underlying cause of PAH, Cambridge spinout Morphogen-IX raises about $23M in Series B

Back in the year 2000, a major mutation in familial pulmonary arterial hypertension (PAH) was discovered in the receptor for BMP9 — and for years scientists investigated how this mutation causes PAH and whether that information could be used to treat the debilitating disease.